Inhibitory effect of Yukmijihwang-tang, a traditional herbal formula against testosterone-induced benign prostatic hyperplasia in rats

BMC Complementary and Alternative Medicine

Hyeun-Kyoo Shin²  Chang Seob Seo²  Hye Kyung Ha²  Mee Young Lee²  In Sik Shin¹ 

[1] College of Veterinary Medicine, Chonnam National University, Gwangju, 500-757, Republic of Korea;Basic Herbal Medicine Research Group, Korea Institute of Oriental Medicine, 483 Expo-ro, Yusung-gu, Daejeon 305-811, Republic of Korea

关键词: Dihydrotestosterone;    Benign prostatic hyperplasia;    Traditional herbal formula;    Yukmijihwang-tang;   

Others  :  1232639
DOI  :  10.1186/1472-6882-12-48

 received in 2012-01-02, accepted in 2012-04-20,  发布年份 2012

【 摘 要 】

Background

Yukmijihwang-tang, a traditional herbal formula, has been used for treating disorder, diabetic mellitus and neurosis in China (Liu-wei-di-huang-tang in Chinese), Japan (Lokumijio-to in Japanese) and Korea for many years. In this study, we investigated the effects of Yukmijihwang-tang water extract (YJT) on the development of benign prostatic hyperplasia (BPH) using a rat model of testosterone propionate (TP)-induced BPH.

Methods

A total of 30 rats were divided into five groups. One group was used as a control and the other groups received subcutaneous injections of TP for 4 weeks to induce BPH. YJT (200 or 400 mg/kg) was administered daily for 4 weeks to two groups by oral gavage concurrently with the TP. The animals were euthanized, the prostate and body weights were recorded, and tissues were subjected to hormone assays and histomorphology. In addition, we investigated proliferating cell nuclear antigen (PCNA) expression in the prostate using immunoblotting.

Results

Animals with BPH showed significantly increased absolute and relative prostate weights, increased dihydrotestosterone levels in the serum or prostate and increased PCNA expression in the prostate; however, YJT-treated animals showed significant reductions compared with the animals with TP-induced BPH. Histomorphology also showed that YJT inhibited TP-induced prostatic hyperplasia.

Conclusions

These findings indicate that YJT effectively inhibited the development of BPH and might be a useful drug clinically.

【 授权许可】

   
2012 Shin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

Figure 4 .

【 参考文献 】

• [1]Pais P: Potency of a novel saw palmetto extract, SPET-85, for inhibition of 5alpha-reductase II. Adv Ther 2010, 27:555-563.
• [2]Roehrborn CG: Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am 2011, 95:87-100.
• [3]Barkin J: Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol 2011, 18:14-19.
• [4]McVary KT: A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 2007, 29:387-398.
• [5]Black L, Naslund MJ, Gilbert TD, Davis EA, Ollendorf DA: An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Managed Care 2006, 12:99-110.
• [6]Roehrborn CG, Rosen RC: Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfusozin 10 mg once daily. Clin Interv Aging 2008, 3:511-524.
• [7]Gravas S, Oelke M: Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 2010, 28:9-15.
• [8]Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, Russell D, Tindall D: Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004, 172:1399-1403.
• [9]Bullock TL, Andriole GL: Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Drugs 2006, 11:111-123.
• [10]Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML: Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011, 8:872-884.
• [11]Ha H, Lee JK, Lee HY, Seo CS, Lee MY, Huh JI, Shin H: Evaluation of genotoxicity of Yukmijihwang-tang, a herbal formula. Regul Toxicol Pharmacol 2011, 59:391-396.
• [12]Ha H, Lee JK, Lee HY, Koh WS, Seo CS, Lee MY, Huang DS, Shin H: Safety evaluation of Yukmijihwang-tang: assessment of acute and subchronic toxicity in rats. Evid Based Complement Alternat Med 2011, 2011:672136.
• [13]Song XY, Chen Q, Qi XY: Effects of liuwei dihuang pill on erythrocyte aldose reductase activity in early diabetic nephropathy patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004, 24:1087-1090.
• [14]Kang DG, Sohn EJ, Moon MK, Mun YJ, Woo WH, Kim MK, Lee HS: Yukmijihwang-tang ameliorates ischemia/reperfusion-induced renal injury in rats. J Ethnopharmacol 2006, 104:47-53.
• [15]Kang M, Kim JH, Cho C, Lee KY, Shin M, Hong M, Shim I, Bae H: Effects of Yukmijihwang-tang derivatives (YMJd) on ibotenic acid-induced amnesia in the rat. Biol Pharm Bull 2006, 29:1431-1435.
• [16]Oh MS, Chang MS, Park W, Kim DR, Bae H, Huh Y, Park SK: Yukmijihwang-tang protects against cyclophosphamide-induced reproductive toxicity. Reprod Toxicol 2007, 24:365-370.
• [17]Shim KS, Ma CJ, Kim DS, Ma JY: Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation. J Med Food 2011, 14:1439-1447.
• [18]Shen JJ, Lin CJ, Hiang JL, Hsieh KH, Kuo ML: The effect of liu-wei-di-huang wan on cytokine gene expression from human peripheral blood lymphocytes. Am J Chin Med 2003, 31:247-257.
• [19]Huynh H: Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol 2002, 20:1297-1303.
• [20]Veeresh Babu SV, Veeresh B, Patill AA, Warke YB: Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. Eur J Pharmacol 2010, 625:262-265.
• [21]Arruzazabala ML, Mas R, Molina V, Noa M, Carbajal D, Mendoza N: Effect of D-004, a lipid extract from the Cuban royal palm fruit, on atypical prostate hyperplasia induced by phynylephrine in rats. Drugs R&D 2006, 7:233-241.
• [22]Bisson JF, Hidalgo S, Rozan P, Messaoudi M: Therapeutic effect of ACTICOA powder, a cocoa polyphenolic extract on experimentally induced prostate hyperplasia in Wistar-Unilever rats. J Med Food 2007, 10:628-635.
• [23]Jang H, Ha US, Kim SJ, Yoon BI, Han DS, Yuk SM, Kim SW: Anthocyanin extracted from black soybean reduces prostate weight and promotes apoptosis in the prostatic hyperplasia-induced rat model. J Agric Food Chem 2010, 58:12686-12691.
• [24]Essers J, Theil AF, Baldeyron C, van Cappellen WA, Houtsmuller AB, Kanaar R, Vermeulen W: Nuclear dynamics of PCNA in DNA replication and repair. Mol Cell Biol 2005, 25:9350-9359.
• [25]Li SH, Ryu JH, Park SE, Cho YS, Park JW, Lee WJ, Chun YS: Vitamin C supplementation prevents testosterone-induced hyperplasia of rat prostate by down-regulating HIF-1alpha. J Nutr Biochem 2010, 21:801-808.
• [26]Zhong W, Peng J, He H, Wu D, Han Z, Bi X, Dai Q: Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med 2008, 31:8-15.
• [27]Vikram A, Kushwaha S, Jena GB: Relative influence of testosterone and insulin in the regulation of prostatic cell proliferation and growth. Steroids 2011, 76:416-423.
• [28]Miller J, Tarter TH: Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. Clin Interv Aging 2009, 4:251-258.
• [29]Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R: Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 2008, 72:808-812.
• [30]Carson C, Rittmaster R: The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003, 61:2-7.
• [31]Mizokami A, Koh E, Izumi K, Narimoto K, Takeda M, Honma S, Dai J, Keller ET, Namiki M: Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocr Relat Cancer 2009, 16:1139-1155.
• [32]Tarter TH, Vaughan ED: Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia. Curr Pharm Des 2006, 12:775-783.
• [33]Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M: An overview on 5alpha-reductase inhibitors. Steroids 2010, 75:109-153.